Fareon Open Label Device Clinical Trial

The purpose of this study is to assess the safety and feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to acquired brain injury, Long COVID, traumatic brain injury, myalgic encephalomyelitis (ME/CFS), and other neurodegenerative diagnoses including but not limited to Alzheimer's disease and to collect data on safety and efficacy to inform the design of larger clinical studies.

NCT Number	NCT07600320
Lead Sponsor	Icahn School of Medicine at Mount Sinai
Conditions	Cognitive Dysfunction, Acquired Brain Injury, Traumatic Brain Injury
Enrollment	30 participants
Start Date	2026-05-01
Primary Completion	2027-04-30 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-20